Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BEVACIZUMAB Cause Carbohydrate antigen 125 increased? 141 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 141 reports of Carbohydrate antigen 125 increased have been filed in association with BEVACIZUMAB (JOBEVNE). This represents 0.2% of all adverse event reports for BEVACIZUMAB.

141
Reports of Carbohydrate antigen 125 increased with BEVACIZUMAB
0.2%
of all BEVACIZUMAB reports
17
Deaths
33
Hospitalizations

How Dangerous Is Carbohydrate antigen 125 increased From BEVACIZUMAB?

Of the 141 reports, 17 (12.1%) resulted in death, 33 (23.4%) required hospitalization, and 1 (0.7%) were considered life-threatening.

Is Carbohydrate antigen 125 increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BEVACIZUMAB. However, 141 reports have been filed with the FAERS database.

What Other Side Effects Does BEVACIZUMAB Cause?

Off label use (12,094) Death (8,493) Diarrhoea (4,911) Disease progression (4,653) Fatigue (4,572) Nausea (4,357) Hypertension (4,309) Anaemia (3,221) Vomiting (3,193) Neutropenia (2,875)

What Other Drugs Cause Carbohydrate antigen 125 increased?

NIRAPARIB (1,868) RUCAPARIB CAMSYLATE (562) OLAPARIB (280) LETROZOLE (61) CARBOPLATIN (54) PACLITAXEL (50) DOXORUBICIN (43) PEMBROLIZUMAB (36) COVID-19 VACCINE NOS (27) RIBOCICLIB (26)

Which BEVACIZUMAB Alternatives Have Lower Carbohydrate antigen 125 increased Risk?

BEVACIZUMAB vs BEVACIZUMAB-AWWB BEVACIZUMAB vs BEVACIZUMAB-BVZR BEVACIZUMAB vs BEVACIZUMAB-MALY BEVACIZUMAB vs BEXAROTENE BEVACIZUMAB vs BEYAZ

Related Pages

BEVACIZUMAB Full Profile All Carbohydrate antigen 125 increased Reports All Drugs Causing Carbohydrate antigen 125 increased BEVACIZUMAB Demographics